![BT Slingsby](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
BT Slingsby
Fondateur chez MINERALYS THERAPEUTICS, INC.
Relations actives
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Takeshi Takahashi | M | 48 |
Pathalys Pharma, Inc.
![]() Pathalys Pharma, Inc. Pharmaceuticals: MajorHealth Technology Pathalys Pharma, Inc. is a late-stage clinical biopharmaceutical company that focuses on developing advanced therapeutics to manage end-stage kidney disease. The company is based in Raleigh, NC. The company's initial asset is Upacicalcet, a novel calcimimetic that has the potential to improve the treatment of secondary hyperparathyroidism in hemodialysis patients. Pathalys Pharma continues to identify other high priority needs and potential solutions for patients with end-stage kidney disease. The company was founded by Ashwin Ram, Mahesh Krishnan, Jay P. Shepard, Brian Taylor Slingsby. The CEO is Neal F. Fowler. | 4 ans |
Ashwin Ram | M | - |
Kirilys Therapeutics, Inc.
![]() Kirilys Therapeutics, Inc. Medical/Nursing ServicesHealth Services Kirilys Therapeutics, Inc. is an American preclinical-stage biopharmaceutical company that focuses on developing multiple precision oncology assets. The company is based in California and is committed to advancing the field of oncology. The company's initial asset is KRLS-017, a novel CDK7 inhibitor that has the potential to improve the treatment of multiple cancers. Kirilys Therapeutics was founded by Takeshi Takahashi, Brian Taylor Slingsby, and Kapil Dhingra, with Brian Taylor Slingsby serving as the CEO since incorporation.
Pathalys Pharma, Inc.
![]() Pathalys Pharma, Inc. Pharmaceuticals: MajorHealth Technology Pathalys Pharma, Inc. is a late-stage clinical biopharmaceutical company that focuses on developing advanced therapeutics to manage end-stage kidney disease. The company is based in Raleigh, NC. The company's initial asset is Upacicalcet, a novel calcimimetic that has the potential to improve the treatment of secondary hyperparathyroidism in hemodialysis patients. Pathalys Pharma continues to identify other high priority needs and potential solutions for patients with end-stage kidney disease. The company was founded by Ashwin Ram, Mahesh Krishnan, Jay P. Shepard, Brian Taylor Slingsby. The CEO is Neal F. Fowler. | - |
Jay Shepard | M | 66 |
Aculys Pharma LLC
![]() Aculys Pharma LLC Pharmaceuticals: MajorHealth Technology Aculys Pharma LLC is a Japanese biopharmaceutical company that focuses on developing and commercializing innovations in the fields of neurology and psychiatry. The company is based in Japan and was established in January 2021. The company's philosophy is to act as a catalyst to access innovative medical care in the field of neuropsychiatry. Aculys Pharma develops and commercializes novel pharmaceuticals and provides innovations for better medical care to patients, their families, healthcare professionals, and society.
Pathalys Pharma, Inc.
![]() Pathalys Pharma, Inc. Pharmaceuticals: MajorHealth Technology Pathalys Pharma, Inc. is a late-stage clinical biopharmaceutical company that focuses on developing advanced therapeutics to manage end-stage kidney disease. The company is based in Raleigh, NC. The company's initial asset is Upacicalcet, a novel calcimimetic that has the potential to improve the treatment of secondary hyperparathyroidism in hemodialysis patients. Pathalys Pharma continues to identify other high priority needs and potential solutions for patients with end-stage kidney disease. The company was founded by Ashwin Ram, Mahesh Krishnan, Jay P. Shepard, Brian Taylor Slingsby. The CEO is Neal F. Fowler. | - |
Srini Akkaraju Akkaraju | M | 56 | 3 ans | |
Krishnan Mahesh /davita/ | - | - |
Pathalys Pharma, Inc.
![]() Pathalys Pharma, Inc. Pharmaceuticals: MajorHealth Technology Pathalys Pharma, Inc. is a late-stage clinical biopharmaceutical company that focuses on developing advanced therapeutics to manage end-stage kidney disease. The company is based in Raleigh, NC. The company's initial asset is Upacicalcet, a novel calcimimetic that has the potential to improve the treatment of secondary hyperparathyroidism in hemodialysis patients. Pathalys Pharma continues to identify other high priority needs and potential solutions for patients with end-stage kidney disease. The company was founded by Ashwin Ram, Mahesh Krishnan, Jay P. Shepard, Brian Taylor Slingsby. The CEO is Neal F. Fowler. | - |
Adam Levy | M | 46 | 2 ans | |
Derek DiRocco | M | 43 | 2 ans | |
Takeshi Takahashi | M | - |
Kirilys Therapeutics, Inc.
![]() Kirilys Therapeutics, Inc. Medical/Nursing ServicesHealth Services Kirilys Therapeutics, Inc. is an American preclinical-stage biopharmaceutical company that focuses on developing multiple precision oncology assets. The company is based in California and is committed to advancing the field of oncology. The company's initial asset is KRLS-017, a novel CDK7 inhibitor that has the potential to improve the treatment of multiple cancers. Kirilys Therapeutics was founded by Takeshi Takahashi, Brian Taylor Slingsby, and Kapil Dhingra, with Brian Taylor Slingsby serving as the CEO since incorporation. | - |
Jon Congleton | M | 60 | 4 ans | |
Kapil Dhingra | M | 64 |
Kirilys Therapeutics, Inc.
![]() Kirilys Therapeutics, Inc. Medical/Nursing ServicesHealth Services Kirilys Therapeutics, Inc. is an American preclinical-stage biopharmaceutical company that focuses on developing multiple precision oncology assets. The company is based in California and is committed to advancing the field of oncology. The company's initial asset is KRLS-017, a novel CDK7 inhibitor that has the potential to improve the treatment of multiple cancers. Kirilys Therapeutics was founded by Takeshi Takahashi, Brian Taylor Slingsby, and Kapil Dhingra, with Brian Taylor Slingsby serving as the CEO since incorporation. | - |
Neal Fowler | M | 62 |
Pathalys Pharma, Inc.
![]() Pathalys Pharma, Inc. Pharmaceuticals: MajorHealth Technology Pathalys Pharma, Inc. is a late-stage clinical biopharmaceutical company that focuses on developing advanced therapeutics to manage end-stage kidney disease. The company is based in Raleigh, NC. The company's initial asset is Upacicalcet, a novel calcimimetic that has the potential to improve the treatment of secondary hyperparathyroidism in hemodialysis patients. Pathalys Pharma continues to identify other high priority needs and potential solutions for patients with end-stage kidney disease. The company was founded by Ashwin Ram, Mahesh Krishnan, Jay P. Shepard, Brian Taylor Slingsby. The CEO is Neal F. Fowler. | - |
Daphne Karydas | F | 49 | 1 ans | |
Glenn Sblendorio | M | 68 | 1 ans | |
David Rodman | M | 69 | 3 ans | |
GALYM IMANBAYEV | M | - |
Kirilys Therapeutics, Inc.
![]() Kirilys Therapeutics, Inc. Medical/Nursing ServicesHealth Services Kirilys Therapeutics, Inc. is an American preclinical-stage biopharmaceutical company that focuses on developing multiple precision oncology assets. The company is based in California and is committed to advancing the field of oncology. The company's initial asset is KRLS-017, a novel CDK7 inhibitor that has the potential to improve the treatment of multiple cancers. Kirilys Therapeutics was founded by Takeshi Takahashi, Brian Taylor Slingsby, and Kapil Dhingra, with Brian Taylor Slingsby serving as the CEO since incorporation. | - |
Patrick Treanor | M | - |
Pathalys Pharma, Inc.
![]() Pathalys Pharma, Inc. Pharmaceuticals: MajorHealth Technology Pathalys Pharma, Inc. is a late-stage clinical biopharmaceutical company that focuses on developing advanced therapeutics to manage end-stage kidney disease. The company is based in Raleigh, NC. The company's initial asset is Upacicalcet, a novel calcimimetic that has the potential to improve the treatment of secondary hyperparathyroidism in hemodialysis patients. Pathalys Pharma continues to identify other high priority needs and potential solutions for patients with end-stage kidney disease. The company was founded by Ashwin Ram, Mahesh Krishnan, Jay P. Shepard, Brian Taylor Slingsby. The CEO is Neal F. Fowler. | 3 ans |
Jessica Ibbitson | F | - | 3 ans | |
Minji Kim | M | - | - |
Graphique Relationnel
Relation dans plusieurs entreprises
Anciennes relations
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Alexander G. Asam | M | 58 | 3 ans | |
Olivier Litzka | M | 56 | 2 ans | |
Roger Zhang | M | - | - |
Statistiques
Pays | Relations | % du total |
---|---|---|
Etats-Unis | 21 | 100,00% |
Japon | 1 | 4,76% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- BT Slingsby
- Réseau Personnel